Your browser doesn't support javascript.
loading
A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (µ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty.
Singla, Neil; Minkowitz, Harold S; Soergel, David G; Burt, David A; Subach, Ruth Ann; Salamea, Monica Y; Fossler, Michael J; Skobieranda, Franck.
Affiliation
  • Singla N; Lotus Clinical Research, Pasadena, CA.
  • Minkowitz HS; Memorial Hermann Memorial City Medical Center, Houston, TX.
  • Soergel DG; Trevena, Inc, King of Prussia, PA, USA.
  • Burt DA; Trevena, Inc, King of Prussia, PA, USA.
  • Subach RA; Trevena, Inc, King of Prussia, PA, USA.
  • Salamea MY; Trevena, Inc, King of Prussia, PA, USA.
  • Fossler MJ; Trevena, Inc, King of Prussia, PA, USA.
  • Skobieranda F; Trevena, Inc, King of Prussia, PA, USA.
J Pain Res ; 10: 2413-2424, 2017.
Article in En | MEDLINE | ID: mdl-29062240
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Language: En Journal: J Pain Res Year: 2017 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Language: En Journal: J Pain Res Year: 2017 Document type: Article Affiliation country: